Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, hosted a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on March 26, 2020.
Tagged with: Capricor Therapeutics
8 days ago
Sarepta Therapeutics and Codiak Biosciences collaborate to research and develop exosome-based therapeutics for rare diseases
16 days ago